中文名称: | SU 5402 | ||||
---|---|---|---|---|---|
英文名称: | SU 5402 | ||||
别名: | SU 5402 3-[4-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid | ||||
CAS No: | 215543-92-3 | 分子式: | C17H16N2O3 | 分子量: | 296.32054 |
CAS No: | 215543-92-3 | ||||
分子式: | C17H16N2O3 | ||||
分子量: | 296.32054 |
基本信息
产品编号:S11101 |
|||||
产品名称:SU 5402 |
|||||
CAS: |
215543-92-3 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
六个月 |
||
分子量 |
296.32 |
-20℃ |
一个月 |
||
化学名: |
|
||||
Solubility (25°C) |
体外 |
DMSO |
59mg/mL (199.1mM) |
||
Ethanol |
Insoluble |
||||
Water |
Insoluble |
||||
体内(现配现用) |
|
|
|||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
3.3747mL |
16.8737mL |
33.7473mL |
5mM |
0.6749mL |
3.3747mL |
6.7495mL |
10mM |
0.3375mL |
1.6874mL |
3.3747mL |
50mM |
0.0675mL |
0.3375mL |
0.6749mL |
生物活性
产品描述 |
一种有效的多靶点受体酪氨酸激酶抑制剂,作用于 VEGFR2,FGFR1 和 PDGFRβ,IC50 分别为 20nM,30nM 和 510nM。 |
||
靶点/IC50 |
VEGFR2 |
FGFR1 |
PDGFRβ |
20nM |
30nM |
510nM |
|
体外研究 |
SU 5402 is cocrystallized with the catalytic domain of FGF-R1 (flg-1) and is found to inhibit yrosine phosphorylation of VEGFR2 (Flk-1/KDR) and PDGF-R in NIH 3T3 cells with IC50 values of 0.4 and 60.9μM, respectively[1]. In order to investigate whether phosphorylation of PKM2 and LDHA is mediated in FGFR1-specific manner, FTC-133 are treated with receptor tyrosine kinase inhibitors Dovitinib and SU 5402 (SU-5402). Dovitinib treatment results in significant decrease of phosphorylation status at a concentration of 100nM after four hours of incubation for both PKM2 and LDHA. No significant changes are seen when administered at concentrations of 1nM and 10nM. SU 5402 administration leads to a sigificant decrease of PKM2 and LDHA phosphorylation at a concentration of 20μM. |
||
体内研究 |
Inhibition of FGFR1 with SU 5402 (SU5402) administered to ΔF508-CFTR homozygous mice results in partial ΔF508-CFTR.rescue, as shown by an increase in saliva secretion, a surrogate "sweat test" assay in mice. As salivary secretion is often sex dependent, only male mice are chosen for these experiments. Our results indicate that treatment of the ΔF508-CFTR mice with SU 5402 restores the saliva secretion level to ~10% of that observed for the wild-type CFTR mice, which suggests that SU 5402 can have therapeutic benefits to Cystic Fibrosis (CF). The selective FGFR1 inhibitor SU 5402 (SU5402) prevents and/or reverses PH induced by MCT (monocrotaline) in rats. In rats treated with SU 5402 on days 21 to 42 after the MCT injection, evaluations on day 42 show marked decreases in pulmonary artery pressure (PAP), RV/(LV+S), and distal artery muscularization compare with rats treated with the vehicle (saline). |
推荐实验方法(仅供参考)
细胞实验: |
|
8505C and FTC133 cells are grown in DMEM/F12 suppplemented with 10% FCS and 1% PenStrep and incubated at 37℃, 5% CO2. For B-CPAP RPMI 1640 medium is used. FGFR1 inhibition experiments are performed on FTC133 cells by employment of Receptor Tyrosine Kinase Inhibitors TKI-258 (Dovitinib) and SU 5402 (20μM). Inhibition is conducted over 4h with the indicated inhibitor concentrations. Control cells receive corresponding concentrations of DMSO. |
动物实验: |
|
Rats To assess the potential effects of the FGFR1 inhibitor SU 5402 on established PH, adult male Wistar rats (200-250g) are given MCT (60mg/kg s.c.), left untreated for 21 days, then randomly divided into 2 groups (10 animals in each group), of which one is treated with SU 5402 (25mg/kg/day) and the other given the vehicle, from day 21 to day 42. All treatments are given once a day by s.c. injection. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )